116 related articles for article (PubMed ID: 26255490)
1. [Research on regulation mechanism of osteoclast differentiation].
Song CY; Peng B; Shen JY; Jin HT; Xiao LW; Tong PJ
Zhongguo Gu Shang; 2015 Jun; 28(6):580-4. PubMed ID: 26255490
[TBL] [Abstract][Full Text] [Related]
2. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
[TBL] [Abstract][Full Text] [Related]
3. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
4. Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.
Tanaka S
Am J Nephrol; 2007; 27(5):466-78. PubMed ID: 17652963
[TBL] [Abstract][Full Text] [Related]
5. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
6. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
Dougall WC; Chaisson M
Cancer Metastasis Rev; 2006 Dec; 25(4):541-9. PubMed ID: 17180711
[TBL] [Abstract][Full Text] [Related]
7. [The OPG/RANKL/RANK system and bone resorptive disease].
Liu JZ; Ji ZL; Chen SM
Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
[TBL] [Abstract][Full Text] [Related]
8. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
[TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption.
Aubin JE; Bonnelye E
Osteoporos Int; 2000; 11(11):905-13. PubMed ID: 11193242
[TBL] [Abstract][Full Text] [Related]
10. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
11. RANK signalling in bone lesions with osteoclast-like giant cells.
Won KY; Kalil RK; Kim YW; Park YK
Pathology; 2011 Jun; 43(4):318-21. PubMed ID: 21532526
[TBL] [Abstract][Full Text] [Related]
12. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin and osteoprotegerin ligand expression during human marrow stromal cell differentiation and their effect on osteoclast formation.
Yang L; Hai Y; Zhou JL
Chin Med J (Engl); 2011 Jul; 124(13):2033-7. PubMed ID: 22088466
[TBL] [Abstract][Full Text] [Related]
14. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
[TBL] [Abstract][Full Text] [Related]
15. [Genomic approaches to bone and joint diseases. Mutations of RANK, OPG and RANKL genes found in humans].
Kobayashi Y; Takahashi N
Clin Calcium; 2008 Feb; 18(2):202-9. PubMed ID: 18245890
[TBL] [Abstract][Full Text] [Related]
16. [Bone and Stem Cells. Molecular mechanisms of the differentiation and activation of osteoclasts derived from hematopoietic cells].
Hayashi M; Nakashima T
Clin Calcium; 2014 Apr; 24(4):487-500. PubMed ID: 24681494
[TBL] [Abstract][Full Text] [Related]
17. Zebrafish scales respond differently to in vitro dynamic and static acceleration: analysis of interaction between osteoblasts and osteoclasts.
Kitamura K; Takahira K; Inari M; Satoh Y; Hayakawa K; Tabuchi Y; Ogai K; Nishiuchi T; Kondo T; Mikuni-Takagaki Y; Chen W; Hattori A; Suzuki N
Comp Biochem Physiol A Mol Integr Physiol; 2013 Sep; 166(1):74-80. PubMed ID: 23632157
[TBL] [Abstract][Full Text] [Related]
18. [Cytokines in bone diseases. Genetic disorders of RANKL-RANK-OPG system].
Tokuyama N; Tanaka S
Clin Calcium; 2010 Oct; 20(10):1532-8. PubMed ID: 20890036
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
[TBL] [Abstract][Full Text] [Related]
20. [Control of bone resorption by RANKL-RANK system].
Harada S; Takahashi N
Clin Calcium; 2011 Aug; 21(8):1121-30. PubMed ID: 21814016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
